IL316751A - Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies - Google Patents

Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies

Info

Publication number
IL316751A
IL316751A IL316751A IL31675124A IL316751A IL 316751 A IL316751 A IL 316751A IL 316751 A IL316751 A IL 316751A IL 31675124 A IL31675124 A IL 31675124A IL 316751 A IL316751 A IL 316751A
Authority
IL
Israel
Prior art keywords
antibodies
psma
methods
combination
prostate cancer
Prior art date
Application number
IL316751A
Other languages
English (en)
Hebrew (he)
Inventor
Elizabeth Miller
Sabina Sandigursky
Israel Lowy
Frank Seebach
Original Assignee
Regeneron Pharma
Elizabeth Miller
Sabina Sandigursky
Israel Lowy
Frank Seebach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Elizabeth Miller, Sabina Sandigursky, Israel Lowy, Frank Seebach filed Critical Regeneron Pharma
Publication of IL316751A publication Critical patent/IL316751A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL316751A 2022-05-16 2023-05-15 Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies IL316751A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263342548P 2022-05-16 2022-05-16
PCT/US2023/022243 WO2023224912A1 (en) 2022-05-16 2023-05-15 Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
IL316751A true IL316751A (en) 2025-01-01

Family

ID=86764360

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316751A IL316751A (en) 2022-05-16 2023-05-15 Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and anti-CD3 alone or in combination with anti-PD-1 antibodies

Country Status (10)

Country Link
US (1) US20250304714A1 (enExample)
EP (1) EP4525992A1 (enExample)
JP (1) JP2025517336A (enExample)
KR (1) KR20250010677A (enExample)
CN (1) CN119421723A (enExample)
AU (1) AU2023272836A1 (enExample)
CA (1) CA3253070A1 (enExample)
IL (1) IL316751A (enExample)
MX (1) MX2024014019A (enExample)
WO (1) WO2023224912A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026024863A2 (en) * 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
JP7215997B2 (ja) * 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
CA3136892A1 (en) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating renal cancer with an anti- psma/cd3 antibody
AR118720A1 (es) * 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
EP3986933A1 (en) * 2019-06-21 2022-04-27 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
WO2022060878A1 (en) * 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer

Also Published As

Publication number Publication date
CN119421723A (zh) 2025-02-11
MX2024014019A (es) 2025-03-07
JP2025517336A (ja) 2025-06-05
EP4525992A1 (en) 2025-03-26
WO2023224912A1 (en) 2023-11-23
KR20250010677A (ko) 2025-01-21
CA3253070A1 (en) 2023-11-23
AU2023272836A1 (en) 2024-12-12
US20250304714A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
IL318426A (en) Methods for treating metastatic castration-resistant prostate cancer using bispecific antibodies against PSMA and CD28 in combination with anti-PD-1 antibodies
SG11202012137UA (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
IL259588B1 (en) Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
MY203469A (en) Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
PH12021550278A1 (en) Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
MX2021012767A (es) Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
MX2024005392A (es) Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
IL286337A (en) Cancer treatment with her2xcd3 bispecific antibodies in combination with anti-her2 mab
MX2020002301A (es) Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
IL319877A (en) Methods for treating cancer with bispecific EGFR X CD28 antibodies alone or in combination with anti-PD-1 antibodies
IL304600A (en) Methods for treating cancer using anti-tigit antibodies in combination with anti-pd1 antibodies
ZA202204423B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
MX2025006535A (es) Anticuerpos biespecificos que se dirigen a pd1 y vegf
IL313864A (en) Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
ZA202204422B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40122754A (en) Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
HK40128565A (zh) 使用双特异性抗psma×抗cd28抗体与抗pd-1抗体组合来治疗转移性去势抵抗性前列腺癌的方法
IL312813A (en) Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4
AU2024362771A1 (en) Combination treatment of prostate cancers with two bispecific antibodies
IL325956A (en) Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
ZA202204252B (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40118892A (en) Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
EP4308595A4 (en) DNA-ENCODED BISPECIFIC ANTIBODIES AGAINST IL13RALPHA2 AND METHODS FOR USE IN CANCER THERAPY
CA3269085A1 (en) Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
HK40130891A (en) Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies